Format

Send to

Choose Destination
Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5.

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Author information

1
Hematology Section, Department of Medical Sciences, Azienda Ospedaliero-Universitaria, Arcispedale S. Anna, University of Ferrara, Ferrara, Italy.
2
IRCCS Policlinico S. Matteo Foundation, Pavia, Italy.
3
Clinical Pharmacology and Pharmacogenetics Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.
4
Gastroenterology and Transplant Hepatology, "Papa Giovanni XXIII" Hospital, Bergamo, Italy.
5
Università Vita-Salute San Raffaele and IRCCS Istituto Scientifico San Raffaele, Milan, Italy.
6
Division of Gastroenterology, San Giovanni Battista Hospital, University of Torino, Turin, Italy.
7
Department of Hematology, Niguarda Cancer Center Niguarda Hospital Milano, Milan, Italy.
8
Department of Diseases of the Thorax, Ospedale GB Morgagni, Forlì, Italy.
9
Department of Respiratory Diseases & Allergy, Aarhus University Hospital, Aarhus, Denmark.
10
Infectious Disease Unit, Teaching Hospital S. Orsola-Malpighi, Alma Mater Studiorum - University of Bologna, Bologna, Italy.
11
Institute of Hematology Lorenzo e Ariosto Seràgnoli, University of Bologna, Bologna, Italy.

Abstract

The introduction of new therapeutic agents in chronic lymphocytic leukemia (CLL) and follicular lymphoma (FL), including the new kinase inhibitor idelalisib, has changed the therapeutic landscape of these diseases. However, the use of idelalisib is associated with a peculiar profile of side effects, which require an optimization of the current approach to prophylaxis and supportive treatment. Moving from the recognition that the abovementioned issue represents an unmet need in CLL and FL, a multidisciplinary panel of experts was convened to produce a consensus document aiming to provide practical recommendations for the management of the side effects during idelalisib therapy for CLL and FL. The present publication represents a consensus document from a series of meetings held during 2017. The Panel generated clinical key questions using the criterion of clinical relevance through a Delphi process and explored 4 domains, ie, diarrhea/colitis, transaminitis, pneumonitis, and infectious complications. Using the consensus method, the Panel was able to shape recommendations which may assist hematologist to minimize adverse events and guarantee adherence to treatment in patients with CLL and FL candidate to receive idelalisib.

KEYWORDS:

adverse events; chronic lymphocytic leukemia; follicular lymphoma; idelalisib

PMID:
30187496
PMCID:
PMC6585802
DOI:
10.1002/hon.2540
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center